Cancer arises through the acquisition of oncogenic mutations 1 . How such oncogenic mutations affect the rate of stem and progenitor cell proliferation and the proportion of divisions that result in symmetric and asymmetric fate is currently poorly understood. Recent studies following oncogenic activation in mouse gut before tumour formation showed that intestinal stem cells (SCs) acquire a proliferative advantage over their wild-type neighbours, leading to precocious clonal fixation of mutant crypts 2,3 . However, the question of whether and how mutant crypts expand and progress into invasive tumours remains unknown.
Cancer arises through the acquisition of oncogenic mutations 1 . How such oncogenic mutations affect the rate of stem and progenitor cell proliferation and the proportion of divisions that result in symmetric and asymmetric fate is currently poorly understood. Recent studies following oncogenic activation in mouse gut before tumour formation showed that intestinal stem cells (SCs) acquire a proliferative advantage over their wild-type neighbours, leading to precocious clonal fixation of mutant crypts 2, 3 . However, the question of whether and how mutant crypts expand and progress into invasive tumours remains unknown.
Basal cell carcinoma (BCC) is the most frequently occurring type of tumour in humans, with more than 5 million new cases diagnosed each year worldwide. BCCs arise from the constitutive activation of the hedgehog (HH) pathway through either Patched (Ptch1) loss of function or Smoothened (Smo) gain of function 4 . Different mouse models of BCC using Ptch1 deletion or oncogenic SmoM2 mutant expression induce the formation of tumours that resemble superficial human BCC 5 . The skin epidermis contains distinct types of SCs that contribute to the homeostasis of discrete regions of epidermis 6 . Interfollicular epidermis (IFE) is maintained by SCs targeted by K14-CreER, that drives the expression of inducible CreER under the control of the Keratin 14 promoter; and committed progenitors (CPs) targeted by Inv-CreER, in which the CreER is expressed under the control of the Involucrin (Inv) promoter in tail, ear, back and ventral skin epidermis 7, 8 . Activation of oncogenic HH signalling through SmoM2 expression or Ptch1 deletion in these different tissues using K14-CreER, which targets both SCs and CPs, induces BCC formation 7, [9] [10] [11] [12] . However, the question of whether and how SmoM2 expression in SCs and/or CPs drives BCC formation remains unresolved.
SCs but not CPs initiate BCC formation
To determine whether SCs and CPs can induce BCC, we induced oncogenic SmoM2 expression exclusively in CPs using Inv-CreER, and in both CPs and SCs using K14-CreER 7 at the same clonal density ( Fig. 1a and Extended Data Fig. 1a ). As previously reported, activation of SmoM2 expression using K14-CreER induced BCC, characterized by invasion into the dermis and branched morphology, in both tail and ear epidermis [9] [10] [11] (Fig. 1b) . In sharp contrast, activation of SmoM2 expression in CPs using Inv-CreER lead to pre-neoplastic lesions (including hyperplasia and dysplasia) that did not progress to BCCs (Fig. 1b) . These results suggest that only IFE-SCs can induce BCC following activation of SmoM2, whereas IFE-CPs are highly resistant to tumour formation.
We then assessed whether the ability of SCs and CPs to initiate BCC was dependent on the oncogene or tumour suppressor gene used to activate HH signalling. To this end, we induced Ptch1 deletion using K14-CreER or Inv-CreER (Fig. 1c ). Ptch1 deletion using K14-CreER led to BCCs arising from the IFE and the infundibulum (Fig. 1c) . In contrast, Ptch1 deletion using Inv-CreER, which targets some basal cells in the back and ventral skin epidermis 8 , did not lead to the rapid development of BCC, and only rare and small BCCs were observed 24 weeks after induction ( Fig. 1c, d) . These results reveal that only IFE/infundibulum SCs can induce BCC formation, whereas CPs are highly resistant, irrespective of the oncogene or tumour suppressor gene used to activate HH signalling and body location (tail, ear, back and ventral skin).
Two distinct self-maintained compartments, scale and interscale, have been described in tail epidermis 13 . To assess whether cells located in these two compartments respond equally to oncogenic activation, we performed immunofluorescence using a scale-specific marker (K31) and SmoM2-YFP to detect the Smoothened oncogene (SmoM2) fused to YFP on whole-mount tail epidermis. Notably, we found that BCCs arose from K14-CreER SmoM2-targeted cells located only in the interscale ( Fig. 1e ). K14 clones in the interscale progressively lost their normal differentiation program, as evidenced by the loss of spinous-like cells, became hyperplastic, then dysplastic ( Fig. 1f and Extended Data Fig. 1b, c) . From 4 to 8 weeks after induction, around 15% of clones had progressed into BCC in interscale, increasing to 40% after 24 weeks (Fig. 1e, f) . In contrast, K14 clones in scale never progressed to BCC, and maintained a normal differentiation program for an extended period, despite clonal expansion mediated by SmoM2 expression (Fig. 1e, f and Extended Data Fig. 1b, c) .
The changes in cell dynamics after oncogenic mutation that lead to the development of tumours are currently unknown. Here, using skin epidermis as a model, we assessed the effect of oncogenic hedgehog signalling in distinct cell populations and their capacity to induce basal cell carcinoma, the most frequent cancer in humans. We found that only stem cells, and not progenitors, initiated tumour formation upon oncogenic hedgehog signalling. This difference was due to the hierarchical organization of tumour growth in oncogene-targeted stem cells, characterized by an increase in symmetric self-renewing divisions and a higher p53-dependent resistance to apoptosis, leading to rapid clonal expansion and progression into invasive tumours. Our work reveals that the capacity of oncogene-targeted cells to induce tumour formation is dependent not only on their long-term survival and expansion, but also on the specific clonal dynamics of the cancer cell of origin.
Together, these data indicate that the fate of oncogene-targeted cells and the ability of these cells to progress into BCC depends both on their location (scale versus interscale) and cellular origin (SC versus CP). This prompted us to investigate whether there are regional differences in SC potential in tail epidermis even under homeostatic conditions.
Homeostasis of the interscale epidermis
To gain quantitative insight into regional variation in SC potential, we performed lineage tracing at homeostasis to determine whether scale and interscale are differentially maintained. To this end, we compared the evolution of K14-CreER/Rosa-YFP-targeted and Inv-CreER/Rosa-YFP-targeted cells at single-cell resolution over a 24-week time course. Interestingly, although both broad, the distributions of clone sizes in the two regions became increasingly divergent ( Fig. 2a, b and Extended Data Fig. 2 ), confirming the importance of regionalization in cellular dynamics (Supplementary Theory) .
Consistent with our previous study 7 , the evolution of the mean clone size of progenitors targeted by Inv-CreER in the interscale fits well with the targeting of an equipotent CP population presenting a small but statistically significant imbalance in fate towards terminal differentiation ( Fig. 2c, d) . Similarly, the evolution of mean clone size for K14-CreER cells is consistent with the additional targeting of a long-term selfrenewing SC population that divides more slowly than CPs ( Fig. 2c, d ).
To define quantitatively the dynamics of these two populations (cell-cycle times, relative proportion of SCs and CPs labelled by the K14-CreER and their fate probabilities), we made a joint fit to the basal and suprabasal mean clone sizes, and extracted optimal parameters and confidence intervals (Supplementary Theory).
To verify independently the predictions of the model, the persistence of Inv-CreER-and K14-CreER-targeted clones was used to infer the respective labelled cell fractions. As expected from the labelling of the CP population, for Inv-CreER-targeted clones, we found that the labelled cell fraction decreased over time ( Fig. 2e ). In contrast, for K14-CreER-targeted clones, the labelled cell fraction increased over time, consistent with the preferential targeting of the SC population ( Fig. 2e ). Notably, we obtained excellent predictions for the labelled cell fraction for both K14-CreER and Inv-CreER using parameters extracted independently from the fit to the mean clone sizes ( Fig. 2e) . These results support a SC and CP hierarchy, and rule out the possibility that the differences between K14-CreER-and Inv-CreER-targeted clones are the consequence of differential short-term 'priming' of induced cells (Extended Data Fig. 3a ). Importantly, the hierarchical model also predicted accurately the complete distribution of clone sizes at all time points (Extended Data Fig. 3b , c) for both K14-CreER and Inv-CreER.
In sharp contrast, in the scale region of tail epidermis, both basal and suprabasal clone sizes and persistence of K14-CreER-and Inv-CreER-targeted cells were statistically indistinguishable (Extended Data Fig. 4a, c) . Notably, the labelled cell fraction did not change significantly between 2 weeks and 24 weeks after labelling (Extended Data Fig. 4c ), an indication that K14-CreER and Inv-CreER mark the same balanced CP population 13 . We again validated the model (Extended Data Shedding evolution of clonal persistence, as well as the clone size distribution at all time points (Extended Data Fig. 4c, d) .
These results show that, during homeostasis, interscale is maintained by two discrete populations; a comparatively slow-cycling SC and a more rapidly dividing CP population, whereas scale is maintained by a single CP population. As well as unifying diverging reports of maintenance hierarchy in tail epidermis 7, 13, 14 , these findings raised the question of whether the restriction of BCCs to the interscale correlated with the regional localization of IFE-SCs. To test this hypothesis, we assessed whether the same regionalized lineage hierarchy persisted upon SmoM2 activation.
Oncogene-targeted CPs are frozen into dysplasia
To resolve the cellular dynamics underpinning the differential sensitivity of SCs and CPs to BCC initiation in interscale, we first studied the dynamics and proliferation kinetics of Inv-CreER/Rosa-SmoM2 clones. Oncogenic activation in Inv-CreER CPs lead to an increase of the average basal clone size, total clone size and clonal persistence compared to homeostatic conditions (Fig. 3a, b and Extended Data Fig. 5a -c), as well as abnormal or decreased differentiation ( Fig. 3a and Extended Data Fig. 1 b, c). We assessed the average cell-cycle time of SmoM2 Inv-CreER-targeted cells by first marking proliferating cells using 24 h of EdU administration, followed by variable periods of continuous BrdU administration. From the co-labelling of EdU-BrdU, we found that CPs divided on average every 3.6 ± 0.5 days 4 weeks after SmoM2 expression, 7.2 ± 0.6 days after 8 weeks and 9.8 ± 0.3 days after 12 weeks ( Fig. 3c) , indicating that the average division rate of SmoM2 CPs decreases with time. Surprisingly, division rates were uncorrelated with clone size at all time points, indicating that the decrease occurs independently of clone size or stage of tumour progression (Extended Data Fig. 5d ), and consistent with the Inv-CreER oncogene-targeted cells functioning as a single equipotent population.
As deregulation of apoptosis is also important for cancer formation 1 , we assessed whether apoptosis influences the clonal dynamics of oncogene-targeted CPs. In common with their normal counterpart, Inv-CreER-targeted cells did not show evidence of apoptosis over the first 6 weeks after SmoM2 expression (data not shown). However, from 8 weeks on, about 60% of Inv-CreER-targeted clones that presented hyperplasia or dysplasia, contained about 2-4% of apoptotic cells as measured by active caspase-3 immunostaining ( Fig. 3d and Extended Data Fig. 5e -i).
Taking these rates ( Fig. 3e) as an input, we could obtain an excellent fit to the average clone size ( Fig. 3f ) with cell fate probabilities that remain constant over time, with the proportions of symmetric renewal (PP) to asymmetric division (PD) and symmetric differentiation (DD) set at 39%, 45% and 16% respectively ( Fig. 3g ). This result demonstrates that oncogenic expression in CPs leads to enhanced clonal expansion and survival by promoting symmetric proliferation over terminal differentiation. Such an imbalance would lead to exponential clone growth if it were not counteracted by an ever-diminishing effective proliferation rate, leading to a plateau in the mean basal clone size ( Fig. 3f) . Notably, the model prediction provided a good fit to the clone size distribution at all time points ( Fig. 3h ).
Finally, to further verify the model, a low short-term dose of EdU was used to mark a minority of dividing cells and their fate outcome was recorded 3 days later by quantifying the basal and suprabasal localization of EdU doublets (Extended Data Fig. 5j ). From these results, we could confirm a large imbalance between symmetric division and terminal differentiation (35%).
As the scale is maintained by a single progenitor pool, we investigated whether its response to oncogenic activation was similar to interscale CPs. Notably, after an initial increase, the overall labelled cell fraction remained roughly constant over time in scale between 8 and 24 weeks, at a similar level for both K14-CreER and Inv-CreER (Extended Data Fig. 6a-c ), suggesting that, in sharp contrast to interscale, both populations behave identically upon oncogenic activation (Extended Data Fig. 6d ). Together, these results show that both interscale and scale CPs are resistant to BCC formation upon oncogenic HH signalling, although interscale clones can persist longer owing to a larger fate imbalance and enhanced differentiation defects, whereas scale clones rapidly converge towards balance. However, as human epidermis does not show scale organization, the absence of BCC formation in the scale region might not have human relevance.
Oncogene-targeted SCs progress into BCC
To gain insight into how SmoM2 expression in SCs promotes BCC formation, we then performed a quantitative analysis of K14-CreER/ Rosa-SmoM2 clones. Compared to Inv-targeted clones, SmoM2 expression in K14-targeted cells lead to a more rapid and persistent expansion of a fraction of clones (Fig. 4a, b and Extended Data Fig. 7a -c) that progressed into BCC, as well as the formation of smaller clones that did not show tumour progression (Figs 1e, 4b ). This suggests that, in line with homeostatic conditions, K14-CreER marks a fraction of tumour-like SCs, together with tumour-like CPs, a heterogeneity that we verified using proliferation assays ( Fig. 4c ). Indeed, we found that one population of K14-CreER-targeted cells consisted of small clones that displayed similar proliferation kinetics as Inv-CreER SmoM2 clones, whereas a second population consisted of larger clones, which re-entered cell cycle significantly faster ( Fig. 4c and Extended Data Figs 5d and 7d). The population of small K14-CreER-targeted clones (hyperplasia) also presented higher levels of apoptosis compared to the larger clones ( Fig. 4d and Extended Data Fig. 7e-i) . As a result, even though the proliferation of the larger clones also decreased with time ( Fig. 4e and Extended Data Fig. 7j ), their division rate was consistently higher than the Inv-CreERtargeted population (Fig. 4e ).
To model BCC initiation, we adapted the hierarchical model obtained during homeostasis and fitted jointly the mean basal and suprabasal clone sizes of all K14-CreER SmoM2 clones, taking as input the division rate as well as the fraction of SCs initially labelled by the K14-CreER-determined from measurements at homeostasis, and used the fate choices of SCs as fitting parameters ( Fig. 4f and Extended Data Fig. 7k ). In particular, we posited that SCs are imbalanced towards symmetric renewal, whereas CPs derived from these cells remain slightly imbalanced towards symmetric differentiation with the same fate probability as in homeostasis, which gave a good fit to the average basal clone size (Fig. 4g) . Notably, the measured clone size distributions from 12 weeks onwards could not be fit with a one-progenitor population model, in contrast to the distributions of Inv-CreER SmoM2 clones. Instead, the K14-CreER SmoM2 clone size distributions displayed a 'double-exponential' decay, consistent with the labelling of two distinct populations, as predicted quantitatively by the model (Fig. 4h and Supplementary Theory). This shows that K14-CreER targets tumour-like SCs making imbalanced stochastic fate choices, in addition to targeting the same tumour-like CP population as Inv-CreER.
As a final consistency check, we addressed a key hallmark of the hierarchical model, that SCs give rise to basal CPs in K14-CreER-targeted clones. This predicts that the fraction of cell divisions resulting in two basal cells should be greater in SC-versus CP-targeted clones. Indeed, short-term EdU pulse-chase experiments revealed that, in BCC, most divisions (77%) lead to two basal cells (Extended Data Fig. 7l 
p53 restricts CP progression to BCC
Given the observed differences in apoptosis and division rates between oncogene-targeted SCs and CPs, we assessed whether p53, a tumour suppressor gene frequently mutated in human BCC 15 that controls cell cycle arrest and apoptosis 16 , was differentially activated in SCs and CPs upon SmoM2 activation. Immunohistochemistry revealed that p53 was more frequently found in SmoM2 clones arising from Inv-CreER as compared to K14-CreER mice (Extended data Fig. 8a ). To determine whether p53 stabilization in oncogene-targeted CPs restricts the potential of these progenitors to generate BCC, we deleted p53 together with SmoM2 activation and assessed tumour formation. Interestingly, p53 deletion in Inv-CreER targeted CPs leads to BCC in both ear and tail epidermis (Fig. 5a ). In the tail, BCCs were restricted to the interscale whereas, in the scale, clones only progressed into dysplasia (Fig. 5b, c and Extended Data Fig. 8b) . These results indicate that p53 restricts the competence of SmoM2-targeted CPs of the interscale to progress into BCC.
Although the proportion of clones that progress into BCC continued to be more frequent and more rapid in K14-CreER targeted SCs, at 24 weeks after induction more than half of interscale Inv-CreERtargeted clones had progressed into BCC after p53 deletion (Fig. 5c ). The clonal persistence and clone size were increased upon p53 deletion in both Inv-CreER/Rosa-SmoM2 and K14-CreER/Rosa-SmoM2 interscale clones, although the clones were still bigger and more persistent in K14-targeted cells (Fig. 5b, d and Extended Data Fig. 8c-e ). These results indicate that, upon p53 deletion, both oncogene-targeted CPs and SCs present an increase in self-renewing divisions allowing CPs to acquire the ability to form BCC upon SmoM2 expression.
We next determined whether the observed increase in clone size in the absence of p53 in CPs and SCs was due to a decrease in apoptosis, an increase in proliferation or both. Immunostaining for active caspase-3 8 weeks after oncogenic activation showed that large Inv-CreER/Rosa-SmoM2/p53 fl/fl dysplastic and BCC clones displayed reduced apoptosis, Fig. 8f ). However, apoptosis was unchanged in Inv-CreER p53-deficient hyperplastic clones, suggesting that p53-dependent and -independent mechanisms control apoptosis in oncogene-targeted cells (Fig. 5e, Extended Data Fig. 8g ). EdU-BrdU double-pulse experiments 12 weeks after induction showed that deletion of p53 increased the rate of proliferation in both Inv-CreER and K14-CreER oncogene-targeted cells (Fig. 5f ). According to our model, this increase in the rate of division was sufficient, keeping all other parameters constant, to explain the enhanced tumour growth (Fig. 5g ). This provides additional evidence that growth arrest in oncogene-targeted CPs is a key determinant in their inability to mediate BCC progression in the presence of p53.
In summary, our results demonstrate that p53 restricts the ability of CPs to initiate BCC by promoting apoptosis and inducing cell cycle arrest in oncogene-targeted CPs.
Discussion
In this study, we have defined the quantitative dynamics of BCC initiation at single-cell resolution, from the first oncogenic hit to the development of invasive tumours. These results show that the proliferative hierarchical organization of skin epidermis is a key determinant of tumour development, with only IFE-SCs and not CPs able to initiate BCC following oncogenic HH signalling (Extended data Fig. 9 ). Even though CP-derived clones survive and proliferate for months, they are surprisingly robust to BCC transformation and invasion, becoming 'frozen' in a pre-tumorigenic state. The developmental cerebellar progenitors initiate medulloblastoma upon oncogenic HH signalling 17,18 , suggesting the developmental stage of progenitors may also dictate competence for tumour initiation. The long-term maintenance of some oncogene-targeted CPs contrasts the classical transient-amplifying cells in other compartments, such as hair matrix in the skin or the non-Lgr5 crypt progenitors in gut, which are resistant to tumour initiation because of their short lifespan [19] [20] [21] [22] .
Our results show that IFE-SCs reside solely in the interscale region, and have the unique and regionalized competence to initiate large and invasive BCCs. Notably, this regionalized hierarchical organization at homeostasis was maintained upon SmoM2 activation. Oncogene expression in SCs lead to a more rapid clonal expansion as compared to CPs for two main reasons: the maintenance of hierarchical organization in early pre-neoplastic lesions, leading to increased symmetric self-renewing divisions; and the combined resistance to apoptosis and enhanced proliferation of SC-derived pre-neoplastic lesions, leading to a larger effective growth rate. These two properties allow SC-targeted tumours to escape the frozen state that characterized CP-targeted pre-neoplastic lesions, and thereby progress to an invasive phenotype.
Finally, our results show that p53 restricts the ability of CPs to undergo BCC initiation by promoting apoptosis and inducing cellcycle arrest in oncogene-targeted CPs. Interestingly, although the division rates of CPs and SCs that are p53-deficient are similar, SC-targeted tumours still grow to larger sizes than CP-targeted tumours, suggesting that the hierarchical organization is at least partially maintained even after two oncogenic hits. By establishing that sustained imbalance towards self-renewing divisions and resistance to p53-mediated apoptosis and cell-cycle arrest are the main drivers of tumorigenesis, our results suggest that therapy promoting differentiation, p53 reactivation and apoptosis could present a promising avenue to promote BCC regression and prevent tumour relapse.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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MethOdS
Mice. K14-CreER transgenic mice 23 were kindly provided by E. Fuchs, Rockefeller University; Inv-CreER were generated in our laboratory 8 Mouse colonies were maintained in a certified animal facility in accordance with European guidelines. Experiments involving mice presented in this work were approved by Comité d'Ethique du Bien Être Animal (Université Libre de Bruxelles) under protocol number 483N, that states that animals should be euthanized if they present tumours that exceed 1 cm in diameter. The BCCs observed in this study were microscopic and ranged from 1.5 mm to 100 μ m in diameter and in none of the experiments performed, the tumours exceeded the limit (1 cm in diameter) described in protocol 483N. Female and male animals have been used for all experi ments and equal animal gender ratios have been respected in the majority of the analysis, analysis of the different mutant mice was not blind and sample size was calculated to reach statistical significance. The experiments were not randomized. Fig. 1a ). Mice were killed and analysed at different time points following tamoxifen administration. Immunostaining in sections. The tail, ventral skin and ear skin were embedded in optimal cutting temperature compound (OCT, Sakura) and cut into 5-8 μ m frozen sections using a CM3050S Leica cryostat (Leica Microsystems).
Immunostainings were performed on frozen sections. Owing to the fusion of SmoM2 with YFP, SmoM2-expressing cells were detected using anti-GFP antibody. Frozen sections were dried and then fixed with 4% paraformaldehyde/PBS (PFA) for 10 min at room temperature and blocked with blocking buffer for 1 h (PBS, horse serum 5%, BSA 1%, Triton 0.1%). Skin sections were incubated with primary antibodies diluted in blocking buffer overnight at 4 °C, washed with PBS for 3 × 5 min, and then incubated with Hoechst solution and secondary antibodies diluted in blocking buffer for 1 h at room temperature. Finally, sections were washed with PBS for 3 × 5 min at room temperature and mounted in DAKO mounting medium supplemented with 2.5% Dabco (Sigma). Primary antibodies used were the following: anti-GFP (rabbit, 1:1,000, BD, A11122), anti-K14 (Chicken, 1:4,000, Covance, PCK-153P-0100) and anti-B4-integrin (rat, 1:200, BD, 553745). The following secondary antibodies were used: anti-rabbit, anti-rat, anti-chicken, conjugated to AlexaFluor488 (Molecular Probes) and to rhodamine Red-X (JacksonImmunoResearch). Images of immunostaining in sections were acquired using an Axio Imager M1 microscope, an AxioCamMR3 camera and the Axiovision software (Carl Zeiss). Immunostaining in whole mounts. Whole mounts of tail epidermis were performed as previously described 27 and used to quantify the proportion of surviving clones (Extended Data Fig. 2b) as well as the basal suprabasal and total clone size. Specifically, pieces of tail were incubated for 1 h at 37 °C in EDTA 20 mM in PBS in a rocking plate, then using forceps the dermis and epidermis were separated and the epidermis was fixed for 30 min in PFA 4% in agitation at room temperature and washed 3 times with PBS.
For the immunostaining, tail skin pieces were blocked with blocking buffer for 3 h (PBS, horse serum 5%, Triton 0.8%) in a rocking plate at room temperature. After, the skin pieces were incubated with primary antibodies diluted in blocking buffer overnight at 4 °C, the next day they were washed with PBS-Tween 0.2% for 3 × 10 min at room temperature, and then incubated with the secondary antibodies diluted in blocking buffer for 3 h at room temperature, washed 2 × 10 min with PBS-Tween 0.2% and washed for 10 min in PBS. Finally, they were incubated in Hoechst diluted in PBS for 30 min at room temperature in the rocking plate, washed 3 × 10 min in PBS and mounted in DAKO mounting medium supplemented with 2.5% Dabco (Sigma). Primary antibodies used were the following: anti-GFP (rabbit, 1:100, BD, A11122), anti-GFP (goat, 1:800, Abcam, Ab6673), anti-active-caspase3 (rabbit, 1:600, R&D, AF835), anti-β 4-integrin (rat, 1:200, BD, 553745) and anti-K31 (guinea pig, 1:200, Progen, GP-hHa1). The following secondary antibodies were used: anti-rabbit, anti-rat, anti-chicken, anti-goat and anti-guinea pig, conjugated to AlexaFluor488 (Molecular Probes), to rhodamine Red-X (JacksonImmunoResearch) and to Cy5 (1:400, Jackson ImmunoResearch). Analysis of clone survival, size and apoptosis. Quantification of the proportion of surviving clones, as well as total and basal clone size was determined by counting the number of SmoM2-YFP and YFP-positive cells. in each clone using wholemount tail epidermis. The different clones were imaged using Z-stacks using a confocal microscope LSM 780 (Carl Zeiss) and orthogonal views were used to count the number of basal and total number of SmoM2-YFP or YFP-positive cells in each clone, as well as the number of active-caspase3-positive cells in each clone. K31 staining was used to classify the clones according to their location in the scale or interscale regions. Proliferation assays. To measure the kinetics of cell proliferation, a 24 h continuous pulse of EdU followed with a continuous pulse of BrdU were performed. Specifically, mice received at t = 0 an intraperitoneal injection of EdU (1 mg ml −1 ) and 0.1 mg ml −1 EdU was added to their drinking water for 24 h. The next days the mice received a daily intraperitoneal injection of BrdU (10 mg ml −1 ) and 1 mg ml −1 of BrdU was added to their drinking water during the 8 days of the continuous BrdU pulse. Mice were killed at different time points and whole-mount stainings for the tail were performed. The pieces of tail were first stained for GFP (following the protocol described in the previous section). Second, EdU staining was performed following the manufacturer's instructions (Invitrogen). The pieces of tail were then washed in PBS and fixed again in PFA 4% for 10 min. After they were washed in PBS, incubated for 20 min in HCl 1 M at 37 °C, washed three times with PBS-Tween 0.2% and incubated overnight with Alexa-647-coupled anti-BrdU antibody (mouse, 1:200, BD). The next day the tail pieces were washed in PBS, incubated in Hoechst for 30 min at room temperature in the rocking plate, washed 3 × 10 min in PBS and mounted in DAKO mounting medium supplemented with 2.5% Dabco (Sigma). To quantify the number of cells that incorporated EdU and/or BrdU, Z-stacks were acquired for each individual clone and orthogonal views used to count. Immunohistochemistry. For p53 immunohistochemistry, 4-μ m paraffin sections were deparaffinized, rehydrated, followed by antigen unmasking performed for 20 min at 98 °C in citrate buffer (pH 6) using the PT module. Endogenous peroxydase was blocked using 3% H 2 O 2 (Merck) in methanol for 10 min at room temperature. Endogenous avidin and biotin were blocked using the Endogenous Blocking kit (Invitrogen) for 20 min at room temperature. In p53 staining, nonspecific antigen blocking was performed using For the analysis of the clone size of the K14-CreER/Rosa-YFP mice (Fig. 2a , c and Extended Data Fig. 2 ), we counted clones (both in scale and interscale) from two independent experiments at 1 week and 2 weeks, five independent experiments at 4 weeks, three independent experiments at 8 weeks, two independent experiments at 12 weeks and four independent experiments at 24 weeks. For the analysis of the clone size of the Inv-CreER/Rosa-YFP mice (Fig. 2b, c , Extended Data Fig. 2 ), we counted clones (both in scale and interscale) from two independent experiments at 1 week and 2 weeks, five independent experiments at 4 weeks, three independent experiments at 8 weeks, four independent experiments at 12 weeks and three independent experiments at 24 weeks (see raw data in cited figures (Source Data)).
For the clonal persistence of the K14-CreER/Rosa-YFP mice ( Fig. 2e and Extended Data Fig. 2) , we counted 167, 176, 129, 100, 47 and 246 clones in interscale and 184, 109, 75, 66, 19 and 103 clones in scale from 4, 5, 5, 5, 2 and 4 independent experiments at 1, 2, 4, 8, 12 and 24 w respectively. For 24 weeks, we counted several areas per mice as the number of clones was reduced (see Source Data).
For the clonal persistence of the Inv-CreER/Rosa-YFP mice ( Fig. 2e and Extended Data Fig. 2) , we counted 138, 95, 25, 31, 76 and 54 clones in interscale and 12, 17, 7, 8, 20 and 10 clones in scale from 2, 4, 2, 3, 4 and 3 independent experiments at 1, 2, 4, 8, 12 and 24 weeks respectively. For 12 and 24 weeks, we counted several areas per mice as the number of clones was low (see Source Data).
For the analysis of the clone size of the Inv-CreER/Rosa-SmoM2 mice (Fig. 3b, f For the analysis of the clone size of the K14-CreER/Rosa-SmoM2 mice (Fig. 4b, f , h and Extended Data Figs 6, 7) , we counted clones (both in scale and interscale) from three independent experiments at 1 week, from two independent experiments at 2 weeks, 4 weeks, from six independent experiments at 8 weeks, from four independent experiments at 12 weeks and from two independent experiments at 24 weeks (see Source Data).
For the clonal persistence of the K14-CreER/Rosa-SmoM2 mice (Extended Data Figs 6, 7) , we counted 122, 63, 81, 79, 74 and 68 clones in interscale and 89, 46, 37, 42, 31 and 16 clones in scale from 4, 3, 4, 4, 4 and 4 independent experiments at 1, 2, 4, 8, 12 and 24 weeks respectively (see Source Data).
For the cell proliferation kinetics experiments in the Inv-CreER/Rosa-SmoM2 mice (Fig. 3c, e ): at 4 weeks after induction, we counted 33 clones from 3 independent experiments for 2 days of continuous BrdU, 30 clones from 2 independent experiments for 4 days of continuous BrdU, 33 clones from 2 independent experiments for 6 days of continuous BrdU. At 8 weeks after induction, we counted 41 clones from n = 3 mice for 2 days of continuous BrdU, 16 clones from 2 independent experiments for 4 days of continuous BrdU, 30 clones from 2 independent experiments for 6 days of continuous BrdU and 24 clones from 2 independent experiments for 8 days of continuous BrdU. At 12 weeks after induction, we counted 19 clones from 2 independent experiments for 2 days of continuous BrdU, 26 clones from 2 independent experiments for 4 days of continuous BrdU, 27 clones from 2 independent experiments for 6 days of continuous BrdU and 31 clones from 2 independent experiments mice for 8 days of continuous BrdU. For the 2 weeks after induction data point, we use solely continuous BrdU incorporation, and counted 54 clones from two independent experiments.
For the cell proliferation kinetics experiments in the K14-CreER/Rosa-SmoM2 mice (Fig. 4c, e ): at 4 weeks after induction, we counted 56 clones from 3 independent experiments for 2 days of continuous BrdU, 39 clones from 3 independent experiments for 4 days of continuous BrdU, 29 clones from 3 independent experiments for 6 days of continuous BrdU. At 8 weeks after induction, we counted 30 clones from 2 independent experiments for 2 days of continuous BrdU, 25 clones from 2 independent experiments for 4 days of continuous BrdU, 63 clones from 3 independent experiments for 6 days of continuous BrdU and 41 clones from 3 independent experiments for 8 days of continuous BrdU. At 12 weeks after induction, we counted 20 clones from 2 independent experiments for 2 days of continuous BrdU, 21 clones from 2 independent experiments for 4 days of continuous BrdU, 28 clones from 2 independent experiments for 6 days of continuous BrdU and 26 clones from two independent experiments for 8 days of continuous BrdU.
For the quantification of the clone morphology in absence of p53 interscale (Fig. 5c) For the analysis of the clone size of K14-CreER/Rosa-SmoM2/p53 fl/fl mice ( Fig. 5d, g, Extended Data Fig 8e, d) we counted clones from the interscale from two independent experiments at 1, 2 and 4 weeks, three independent experiments at 8 weeks, four independent experiments at 12 weeks. For the analysis of the clone size of Inv-CreER/Rosa-SmoM2/p53 fl/fl mice (Fig. 5d, g and Extended Data Fig 8e, d) we counted clones from the interscale from two independent experiments at 1 and 2 weeks, three independent experiments at 4 and 8 weeks, four independent experiments at 12 weeks.
For 
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Extended Data Figure 3 | The interscale is maintained by two cell populations during homeostasis. a, Evolution in time of the total labelled cell fraction under three hypotheses. For a perfect single population of equipotent balanced progenitors, the labelled cell fraction remains constant. For a single population of equipotent balanced progenitors displaying short-term priming, the labelled cell fraction increases transiently for the cells primed to divide, and decreases transiently for the cells primed to differentiate, but after the priming period, both fractions remain constant at different values. For two populations organized in a hierarchy, the labelled fraction of the progenitors decreases continuously to zero, while the labelled fraction of the stem cells continuously increases to reach a steady state value, corresponding to its average progeny size. b, Cumulative basal clone size distribution of Inv-CreER/Rosa-YFP clones at homeostasis in the interscale upon tamoxifen administration. c, Cumulative basal clone size distribution of K14-CreER/Rosa-YFP clones at homeostasis in the interscale upon tamoxifen administration. Clonal distributions are plotted in log-plot, error bars indicate s.d., thick lines are the model prediction and shaded areas indicate 95% confidence intervals in the model prediction. 
